These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 24041650)
1. Niacin--a case study for the role of event-driven versus surrogate endpoint trials. Blaha MJ; Michos ED Heart; 2013 Nov; 99(22):1631-2. PubMed ID: 24041650 [No Abstract] [Full Text] [Related]
2. HDL: who needs it? Wierzbicki AS Int J Clin Pract; 2011 Nov; 65(11):1111-3. PubMed ID: 21995687 [No Abstract] [Full Text] [Related]
3. Adjunctive lipid lowering therapy in the era of surrogate endpoints. Silverman MG; Blaha MJ; Blumenthal RS Cardiol Rev; 2011; 19(1):17-22. PubMed ID: 21135598 [TBL] [Abstract][Full Text] [Related]
4. Trial clouds use of niacin with a statin. Harv Heart Lett; 2011 Aug; 21(12):2. PubMed ID: 21991606 [No Abstract] [Full Text] [Related]
5. Search and rescue for hypotheses surviving AIM-HIGH, the niacin therapy earthquake: still problematic after the primary publication. Brinton EA J Clin Lipidol; 2012; 6(4):312-7. PubMed ID: 22836067 [No Abstract] [Full Text] [Related]
6. Niacin: the only vitamin that reduces cardiovascular events. Wierzbicki AS Int J Clin Pract; 2011 Apr; 65(4):379-85. PubMed ID: 21401825 [No Abstract] [Full Text] [Related]
8. [What is the future for niacin after the AIM-HIGH study?]. Cybulska B; Kłosiewicz Latoszek L Kardiol Pol; 2012; 70(3):315-6. PubMed ID: 22430425 [No Abstract] [Full Text] [Related]
12. [Enduracin--a nicotinic acid preparation in the treatment of hypercholesterolemia]. Kardiologiia; 1993; 33(11):67-80. PubMed ID: 8145429 [No Abstract] [Full Text] [Related]
13. Niacin: Time to Believe Outcomes Over Surrogate Outcomes: If Not Now, When? Krumholz HM Circ Cardiovasc Qual Outcomes; 2016 Jul; 9(4):343-4. PubMed ID: 27407051 [No Abstract] [Full Text] [Related]
14. [Nicotinic acid in lipid metabolism disorders]. Ahmed K; Offermanns S Pharm Unserer Zeit; 2007; 36(2):120-5. PubMed ID: 17424997 [No Abstract] [Full Text] [Related]
15. More on niacin: no flush, no good. Harv Health Lett; 2007 Jul; 32(9):7. PubMed ID: 17663076 [No Abstract] [Full Text] [Related]
16. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease? Ahmed MH J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417 [TBL] [Abstract][Full Text] [Related]
17. Use of niacin in the United States and Canada. Jackevicius CA; Tu JV; Ko DT; de Leon N; Krumholz HM JAMA Intern Med; 2013 Jul; 173(14):1379-81. PubMed ID: 23753308 [No Abstract] [Full Text] [Related]
18. Termination of Atherothrombosis Intervention in Metabolic Syndrome with Low High-Density Lipoprotein Cholesterol and High Triglycerides: Impact on Global Health Study and decision to use extended-release niacin in elderly. Shil AB J Am Geriatr Soc; 2011 Dec; 59(12):2397-8. PubMed ID: 22188098 [No Abstract] [Full Text] [Related]
19. New focus on raising HDL "good" cholesterol. But the value of this is not entirely clear. Duke Med Health News; 2012 Feb; 18(2):3. PubMed ID: 22397008 [No Abstract] [Full Text] [Related]
20. Drugs for hypertriglyceridemia. Med Lett Drugs Ther; 2013 Mar; 55(1411):17-9. PubMed ID: 23467119 [No Abstract] [Full Text] [Related] [Next] [New Search]